Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.
Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetrameth...
متن کاملBone-targeted therapy in prostate cancer
Androgen deprivation therapy (ADT) is standard for advanced prostate cancer and is now increasingly used as adjunct therapy in high-risk or locally advanced disease and for the treatment of recurring disease based on rising prostate-specific antigen levels. Testosterone stimulates bone formation directly by stimulating the osteoblast proliferation, inhibiting the apoptosis of both osteoblasts a...
متن کاملMultimodality therapy: bone-targeted radioisotope therapy of prostate cancer.
Accumulating data suggest that bone-seeking radiopharmaceuticals can be used to treat prostate cancer bone metastasis and improve the clinical outcome of patients with advanced prostate cancer. It remains to be elucidated whether radiopharmaceuticals enhance the disruption of the onco-niche or the eradication of micrometastatic cells in the bone marrow. The purpose of this review is to investig...
متن کاملDevelopmental trends in targeted radionuclide therapy of neuroendocrine tumors
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a ...
متن کاملStromal targeted therapy in bone metastatic prostate cancer: promise delivered.
T he ability of epithelial neoplasms to evade both hormonal and cytotoxic therapies is self-evident as the common carcinomas (lung, stomach, breast, colon and prostate) at their metastatic stage are rarely curable with current therapies. Though the precise reasons for incurability are debated, virtually all agree that tumor genetic heterogeneity makes eradication of the tumor difficult given ‘D...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2016
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.115.170746